Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily A Dorairaj

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Current Glaucoma Practice|January 12, 2026
Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging EvidenceMary V Lang, Pranav Vasu, Emily A Dorairaj, et al.
Ophthalmology|February 20, 2025
Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor AgonistPranav Vasu, Emily A Dorairaj, Robert N Weinreb, et al.
Ophthalmology|April 24, 2025
ReplyPranav Vasu, Emily A Dorairaj, Robert N Weinreb, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Current Glaucoma Practice|January 12, 2026
Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging EvidenceMary V Lang, Pranav Vasu, Emily A Dorairaj, et al.
Ophthalmology|February 20, 2025
Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor AgonistPranav Vasu, Emily A Dorairaj, Robert N Weinreb, et al.
Ophthalmology|April 24, 2025
ReplyPranav Vasu, Emily A Dorairaj, Robert N Weinreb, et al.
Pageof 1